Press Release
« Back
Celldex Therapeutics Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer and Society of Neuro-Oncology Annual Meetings
Oct 21, 2013
SITC,
The embargo for all data to be presented at SITC lifts on
-
Data from the solid tumor arm of the Phase 1 dose-escalation study of CDX-1127 will be presented in a poster session entitled "A Phase 1 Study of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors" on
Saturday, November 9 from1:00 pm to 2:00 pm and6:15 pm to 7:15 pm ET .
-
Data from the hematologic arm of the Phase 1 dose-escalation study of CDX-1127 will be presented in a poster session entitled "A Phase 1 Study of an Agonist anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors" on
Saturday, November 9 from1:00 pm to 2:00 pm and6:15 pm to 7:15 pm ET .
-
Data from preclinical combination studies of CDX-1127 with chemotherapies and checkpoint inhibitors will be presented in a poster session entitled "Combination Therapies Augment the Anti-tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models" on
Friday, November 8 from1:00 pm to 2:00 pm and6:15 pm to 7:15 pm ET .
SNO,
The embargo for abstracts lifts on
About
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldextherapeutics.com.
CONTACT: Company Contact:Source:Sarah Cavanaugh Vice President ofIR & Corp Comm Celldex Therapeutics, Inc. (781) 433-3161 scavanaugh@celldextherapeutics.com
News Provided by Acquire Media